News

Moletest Scotland’s nomela® – Why a ‘rule-out’ medical test for melanoma is needed now

Published on: 05/07/2021

Moletest Scotland’s nomela® – Why a ‘rule-out’ medical test for melanoma is needed now
Cancer
Member News

A backlog of referrals for suspected melanoma has grown hugely during the pandemic, adding to an already overwhelmed pathway. The vast majority of referred lesions turn out to be benign. Yet, there is an urgent need for a ‘rule-out’ test to focus resources through early reassurance of cases with no evidence of melanoma. Unlike the promise of automated diagnosis, ‘rule-out’ is technically an early deliverable.

Discover More

Moletest (Scotland) Limited is the developer of nomela® – a rule-out test for melanoma. Our mission is to safely  reduce referrals to Secondary Care as “no evidence of melanoma” by more than 50% generating substantial institutional savings and offering instantaneous patient reassurance.

NEWS​

Related News

May 2025 ECHAlliance Newsletter

22 May 2025

April 2025 ECHAlliance Newsletter

22 May 2025

Rwanda to fully digitise health records by December

19 May 2025

Africa CDC Podcast featuring Jean-Philbert Nsengimana

19 May 2025

AHB Symposium – New Topics

19 May 2025

Health Parliament launches global professional plus membership to strengthen health systems worldwide

19 May 2025

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *